Free Trial Information
BioCentury | Nov 14, 2020
Management Tracks

Legend’s new look at the top; plus VC moves at Medicxi, OSI and Qiming

...of infectious diseases including COVID-19. BC Staff Acutus Medical Inc. Quest PharmaTech Inc. Foghorn...
Read More
BioCentury | Dec 8, 2017
Company News

OncoQuest partners with Tesaro for Phase I/II ovarian cancer combo trial

...In October, the OncoQuest Inc. subsidiary of Quest PharmaTech Inc. (TSX-V:QPT) partnered with Tesaro Inc. (NASDAQ:TSRO) to conduct...
...were not disclosed. Quest PharmaTech Inc. (TSX-V:QPT), Edmonton, Alberta Tesaro Inc. (NASDAQ:TSRO), Waltham, Mass. Business: Cancer Elizabeth S. Eaton oregovomab Zejula Quest PharmaTech Inc. Tesaro...
Read More
BioCentury | Sep 14, 2017
Clinical News

Quest PharmaTech begins Phase I/II of oregovomab for ovarian cancer

...The OncoQuest Inc. subsidiary of Quest PharmaTech Inc. (TSX-V:QPT) began a Phase I/II trial of oregovomab (OvaRex Mab...
...is expected to enroll about 10 patients. Oregovomab is a high-affinity mAb targeting CA 125. Quest PharmaTech Inc....
...Safety; cellular immune response and overall survival (OS) Status: Phase I/II started Milestone: NA Alicia Parker oregovomab OvaRex OvaRex Mab Quest PharmaTech Inc. CA...
Read More
BioCentury | Jul 5, 2017
Company News

Management tracks

...which Bio-Rad Laboratories Inc. (NYSE:BIO) acquired in February. The OncoQuest Inc. immuno-oncology subsidiary of Quest PharmaTech Inc....
Read More
BioCentury | May 17, 2017
Clinical News

OncoQuest begins Phase Ib/IIa of oregovomab in ovarian cancer

...control rate (DCR) and overall survival (OS). Oregovomab is a high-affinity mAb targeting CA 125. Quest PharmaTech Inc....
...disease control rate (DCR) and overall survival (OS) Status: Phase Ib/IIa started Milestone: NA Julian Zhu oregovomab OvaRex OvaRex Mab Quest PharmaTech Inc. CA...
Read More
BioCentury | Feb 10, 2017
Clinical News

Oregovomab: Interim Ph IIb QPT-ORE-002 data

...alone. There was no significant difference in the incidence of adverse events between treatment groups. Quest PharmaTech Inc....
...immunogenicity, clinical response, overall survival (OS) and safety Status: Interim Phase IIb data Milestone: NA Chris Lieu oregovomab Quest PharmaTech Inc. CA...
Read More
BioCentury | Apr 4, 2016
Company News

Quest Pharma, Shenzhen Hepalink Pharmaceutical deal

...monoclonal immunoglobulins. OncoVent will initially focus on pancreatic cancer. Hepalink did not respond to inquiries. Quest PharmaTech Inc....
Read More
BioCentury | Dec 7, 2015
Financial News

Quest Pharma completes private placement of convertible preferred stock

Quest PharmaTech Inc. (TSX-V:QPT), Edmonton, Alberta Business: Dermatology, Cancer, Diagnostic Date completed: 2015-11-18 Type: Private placement of convertible preferred stock Raised: $13 million Shares: 3.5 million Price: $3.74 Investor: Shenzhen Hepalink Pharmaceutical Co. Ltd. Note:...
Read More
BioCentury | Oct 19, 2015
Financial News

Quest Pharma completes private placement

Quest PharmaTech Inc. (TSX-V:QPT), Edmonton, Alberta Business: Dermatology, Cancer, Diagnostic Date completed: 2015-10-13 Type: Private placement Raised: C$2 million ($1.5 million) Shares: 25 million Price: C$0.08 Shares after offering: 150.4 million Investor: Shenzhen Hepalink Pharmaceutical...
Read More
BioCentury | Aug 3, 2015
Financial News

Quest Pharma completes private placement of units

Quest PharmaTech Inc. (TSX-V:QPT), Edmonton, Alberta Business: Dermatology, Cancer, Diagnostic Date completed: 2015-07-27 Type: Private placement of units Raised: C$1 million ($769,600) Units: 16.7 million Price: C$0.06 (unit) Shares after offering: 125.4 million Investors: Institutional...
Read More
Items per page:
1 - 10 of 42
BioCentury | Nov 14, 2020
Management Tracks

Legend’s new look at the top; plus VC moves at Medicxi, OSI and Qiming

...of infectious diseases including COVID-19. BC Staff Acutus Medical Inc. Quest PharmaTech Inc. Foghorn...
Read More
BioCentury | Dec 8, 2017
Company News

OncoQuest partners with Tesaro for Phase I/II ovarian cancer combo trial

...In October, the OncoQuest Inc. subsidiary of Quest PharmaTech Inc. (TSX-V:QPT) partnered with Tesaro Inc. (NASDAQ:TSRO) to conduct...
...were not disclosed. Quest PharmaTech Inc. (TSX-V:QPT), Edmonton, Alberta Tesaro Inc. (NASDAQ:TSRO), Waltham, Mass. Business: Cancer Elizabeth S. Eaton oregovomab Zejula Quest PharmaTech Inc. Tesaro...
Read More
BioCentury | Sep 14, 2017
Clinical News

Quest PharmaTech begins Phase I/II of oregovomab for ovarian cancer

...The OncoQuest Inc. subsidiary of Quest PharmaTech Inc. (TSX-V:QPT) began a Phase I/II trial of oregovomab (OvaRex Mab...
...is expected to enroll about 10 patients. Oregovomab is a high-affinity mAb targeting CA 125. Quest PharmaTech Inc....
...Safety; cellular immune response and overall survival (OS) Status: Phase I/II started Milestone: NA Alicia Parker oregovomab OvaRex OvaRex Mab Quest PharmaTech Inc. CA...
Read More
BioCentury | Jul 5, 2017
Company News

Management tracks

...which Bio-Rad Laboratories Inc. (NYSE:BIO) acquired in February. The OncoQuest Inc. immuno-oncology subsidiary of Quest PharmaTech Inc....
Read More
BioCentury | May 17, 2017
Clinical News

OncoQuest begins Phase Ib/IIa of oregovomab in ovarian cancer

...control rate (DCR) and overall survival (OS). Oregovomab is a high-affinity mAb targeting CA 125. Quest PharmaTech Inc....
...disease control rate (DCR) and overall survival (OS) Status: Phase Ib/IIa started Milestone: NA Julian Zhu oregovomab OvaRex OvaRex Mab Quest PharmaTech Inc. CA...
Read More
BioCentury | Feb 10, 2017
Clinical News

Oregovomab: Interim Ph IIb QPT-ORE-002 data

...alone. There was no significant difference in the incidence of adverse events between treatment groups. Quest PharmaTech Inc....
...immunogenicity, clinical response, overall survival (OS) and safety Status: Interim Phase IIb data Milestone: NA Chris Lieu oregovomab Quest PharmaTech Inc. CA...
Read More
BioCentury | Apr 4, 2016
Company News

Quest Pharma, Shenzhen Hepalink Pharmaceutical deal

...monoclonal immunoglobulins. OncoVent will initially focus on pancreatic cancer. Hepalink did not respond to inquiries. Quest PharmaTech Inc....
Read More
BioCentury | Dec 7, 2015
Financial News

Quest Pharma completes private placement of convertible preferred stock

Quest PharmaTech Inc. (TSX-V:QPT), Edmonton, Alberta Business: Dermatology, Cancer, Diagnostic Date completed: 2015-11-18 Type: Private placement of convertible preferred stock Raised: $13 million Shares: 3.5 million Price: $3.74 Investor: Shenzhen Hepalink Pharmaceutical Co. Ltd. Note:...
Read More
BioCentury | Oct 19, 2015
Financial News

Quest Pharma completes private placement

Quest PharmaTech Inc. (TSX-V:QPT), Edmonton, Alberta Business: Dermatology, Cancer, Diagnostic Date completed: 2015-10-13 Type: Private placement Raised: C$2 million ($1.5 million) Shares: 25 million Price: C$0.08 Shares after offering: 150.4 million Investor: Shenzhen Hepalink Pharmaceutical...
Read More
BioCentury | Aug 3, 2015
Financial News

Quest Pharma completes private placement of units

Quest PharmaTech Inc. (TSX-V:QPT), Edmonton, Alberta Business: Dermatology, Cancer, Diagnostic Date completed: 2015-07-27 Type: Private placement of units Raised: C$1 million ($769,600) Units: 16.7 million Price: C$0.06 (unit) Shares after offering: 125.4 million Investors: Institutional...
Read More
Items per page:
1 - 10 of 42